Investment objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

  • Fund Category U.S. Equity Funds
  • Inception Date Aug 13, 2001
Download fund details    Download fund commentary   

Fund details

Series
Currency
Fund code
MER * (%)
F CAD 35070 0.94%

Portfolio analysis As of Mar 31, 2025

98% 2%
Equity Fixed Income

Asset mix

Equity Sector Allocation
Information Technology54.5%
Health Care22.8%
Communication Services17.6%
Financials3.0%
Consumer Discretionary0.9%
Industrials0.9%
Real Estate0.3%
Top 10 Holdings
% Assets
Microsoft Corp 9.5%
Apple Inc 9.4%
NVIDIA Corp 8.4%
Alphabet Inc - Class A Shares 7.3%
Meta Platforms Inc - Class A Shares 5.9%
Broadcom Inc 3.4%
Eli Lilly & Co 3.1%
UnitedHealth Group Inc 2.6%
Netflix Inc 2.1%
AbbVie Inc 1.9%
Total % of Top 10 Holdings 53.6%

Geographic allocation

Region

Performance analysis

Growth of $10,000 since inception

Calendar returns

Trailing return

1 Mth 3 Mth 6 Mth 1 year 3 years 5 years 10 years Since Inception
-8.7 -8.8 -0.8 9.7 15.2 18.9 15.3 8.1 Fund

Distribution ($)/unit

YTD* 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Total distributions --- --- --- --- --- --- --- --- --- --- ---
Interest --- --- --- --- --- --- --- --- --- --- ---
Canadian dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign taxes paid --- --- --- --- --- --- --- --- --- --- ---
Capital gains --- --- --- --- --- --- --- --- --- --- ---
Return of capital --- --- --- --- --- --- --- --- --- --- ---

* MER (%) is based on actual expenses for the preceding calendar year or most recent half-year period ended June 30 expressed on an annualized basis, depending on availability of date at the time of publication.